Literature DB >> 18345947

Warfarin therapy: in need of improvement after all these years.

Stephen E Kimmel1.   

Abstract

BACKGROUND: Warfarin therapy has been used clinically for over 60 years, yet continues to be problematic because of its narrow therapeutic index and large inter-individual variability in patient response. As a result, warfarin is a leading cause of serious medication-related adverse events, and its efficacy is also suboptimal.
OBJECTIVE: To review factors that are responsible for variable response to warfarin, including clinical, environmental, and genetic factors, and to explore some possible approaches to improving warfarin therapy.
RESULTS: Recent efforts have focused on developing dosing algorithms that included genetic information to try to improve warfarin dosing. These dosing algorithms hold promise, but have not been fully validated or tested in rigorous clinical trials. Perhaps equally importantly, adherence to warfarin is a major problem that should be addressed with innovative and cost-effective interventions.
CONCLUSION: Additional research is needed to further test whether interventions can be used to improve warfarin dosing and outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18345947      PMCID: PMC2855533          DOI: 10.1517/14656566.9.5.677

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  95 in total

1.  Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002).

Authors:  Kamakshi Lakshminarayan; Craig A Solid; Allan J Collins; David C Anderson; Charles A Herzog
Journal:  Stroke       Date:  2006-06-29       Impact factor: 7.914

2.  Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.

Authors:  David L Veenstra; Joyce H S You; Mark J Rieder; Federico M Farin; Hui-Wen Wilkerson; David K Blough; Gregory Cheng; Allan E Rettie
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

Review 3.  Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D Deykin; L Poller; H Bussey
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

4.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.

Authors:  Michael A Hillman; Russell A Wilke; Steven H Yale; Humberto J Vidaillet; Michael D Caldwell; Ingrid Glurich; Richard L Berg; John Schmelzer; James K Burmester
Journal:  Clin Med Res       Date:  2005-08

5.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

6.  A new regimen for starting warfarin therapy in out-patients.

Authors:  A Oates; P R Jackson; C A Austin; K S Channer
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

7.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

Authors:  E Chiquette; M G Amato; H I Bussey
Journal:  Arch Intern Med       Date:  1998 Aug 10-24

Review 8.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.

Authors:  C S Landefeld; R J Beyth
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

9.  Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial.

Authors:  A P A Gadisseur; W G M Breukink-Engbers; F J M van der Meer; A M H van den Besselaar; A Sturk; F R Rosendaal
Journal:  Arch Intern Med       Date:  2003-11-24

10.  A simple technic for predicting daily maintenance dose of warfarin.

Authors:  D B Williams; R C Karl
Journal:  Am J Surg       Date:  1979-04       Impact factor: 2.565

View more
  23 in total

1.  Telephone versus office-based management of warfarin: impact on international normalized ratios and outcomes.

Authors:  Laura G Stoudenmire; Christina E DeRemer; Hazem Elewa
Journal:  Int J Hematol       Date:  2014-06-21       Impact factor: 2.490

2.  The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.

Authors:  Ari Allyn-Feuer; Alex Ade; Jasmine A Luzum; Gerald A Higgins; Brian D Athey
Journal:  Pharmacogenomics       Date:  2018-02-05       Impact factor: 2.533

3.  CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Authors:  Stuart A Scott; Malgorzata Jaremko; Steven A Lubitz; Ruth Kornreich; Jonathan L Halperin; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

4.  Warfarin overdose: a 25-year experience.

Authors:  Michael Levine; Anthony F Pizon; Angela Padilla-Jones; Anne-Michelle Ruha
Journal:  J Med Toxicol       Date:  2014-06

5.  Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.

Authors:  Daniel Weiss; Robert Knight; Simon Zhou; Maria Palmisano; Nianhang Chen
Journal:  Clin Drug Investig       Date:  2015-07       Impact factor: 2.859

6.  Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

Authors:  Kan He; Joseph M Luettgen; Donglu Zhang; Bing He; James E Grace; Baomin Xin; Donald J P Pinto; Pancras C Wong; Robert M Knabb; Patrick Y S Lam; Ruth R Wexler; Scott J Grossman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-02       Impact factor: 2.441

Review 7.  A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation.

Authors:  Amanda Jia Qi Ooi; Chloe Wong; Timothy Wei Ern Tan; Trina Priscilla Ng; Yao Neng Teo; Yao Hao Teo; Nicholas L Syn; Andie H Djohan; Yinghao Lim; Leonard L L Yeo; Benjamin Y Q Tan; Mark Yan-Yee Chan; Kian-Keong Poh; William K F Kong; Ping Chai; Tiong-Cheng Yeo; James W Yip; Ivandito Kuntjoro; Ching-Hui Sia
Journal:  Eur J Clin Pharmacol       Date:  2022-08-09       Impact factor: 3.064

8.  Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits.

Authors:  Donglu Zhang; Kan He; Nirmala Raghavan; Lifei Wang; Earl J Crain; Bing He; Baomin Xin; Joseph M Luettgen; Pancras C Wong
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

9.  Impact of warfarin discharge education program on hospital readmission and treatment costs.

Authors:  Luigi Brunetti; Seung-Mi Lee; Nancy Doherty; David Suh; Jeong-Eun Kim; Sun-Hong Lee; Yong Chan Choi; Dong-Churl Suh
Journal:  Int J Clin Pharm       Date:  2018-03-31

10.  Novel venous thromboembolic disease (VTED) prophylaxis for total knee arthroplasty-aspirin and fish oil.

Authors:  Peter M Bonutti; Nipun Sodhi; Yatindra H Patel; Assem A Sultan; Anton Khlopas; Morad Chughtai; Frank R Kolisek; Nick Williams; Michael A Mont
Journal:  Ann Transl Med       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.